JP2012506884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506884A5 JP2012506884A5 JP2011533630A JP2011533630A JP2012506884A5 JP 2012506884 A5 JP2012506884 A5 JP 2012506884A5 JP 2011533630 A JP2011533630 A JP 2011533630A JP 2011533630 A JP2011533630 A JP 2011533630A JP 2012506884 A5 JP2012506884 A5 JP 2012506884A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- oxidative stress
- hdaci
- arsenic
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 9
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 9
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 230000036542 oxidative stress Effects 0.000 claims 7
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 5
- KJQFBVYMGADDTQ-CVSPRKDYSA-N L-buthionine-(S,R)-sulfoximine Chemical compound CCCCS(=N)(=O)CC[C@H](N)C(O)=O KJQFBVYMGADDTQ-CVSPRKDYSA-N 0.000 claims 4
- 230000001177 retroviral effect Effects 0.000 claims 4
- 241001430294 unidentified retrovirus Species 0.000 claims 4
- IKWTVSLWAPBBKU-UHFFFAOYSA-N a1010_sial Chemical compound O=[As]O[As]=O IKWTVSLWAPBBKU-UHFFFAOYSA-N 0.000 claims 3
- 229910052785 arsenic Inorganic materials 0.000 claims 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical group [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims 3
- 229960002594 arsenic trioxide Drugs 0.000 claims 3
- 230000001973 epigenetic effect Effects 0.000 claims 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 3
- 239000010931 gold Substances 0.000 claims 3
- 229910052737 gold Inorganic materials 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 claims 2
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 claims 2
- 229960005207 auranofin Drugs 0.000 claims 2
- PYGSRODPKOUEJG-UHFFFAOYSA-L cyanoformate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)C#N.[O-]C(=O)C#N PYGSRODPKOUEJG-UHFFFAOYSA-L 0.000 claims 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 2
- 235000003891 ferrous sulphate Nutrition 0.000 claims 2
- 239000011790 ferrous sulphate Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 239000000411 inducer Substances 0.000 claims 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 2
- 229960000237 vorinostat Drugs 0.000 claims 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 108010036164 Glutathione synthase Proteins 0.000 claims 1
- 102100034294 Glutathione synthetase Human genes 0.000 claims 1
- 102000006947 Histones Human genes 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 238000011225 antiretroviral therapy Methods 0.000 claims 1
- 229910000413 arsenic oxide Inorganic materials 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 claims 1
- -1 ferrous metals Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0819857.4 | 2008-10-29 | ||
| GB0819857A GB0819857D0 (en) | 2008-10-29 | 2008-10-29 | Antiviral therapy |
| GB0908952A GB0908952D0 (en) | 2009-05-22 | 2009-05-22 | Antiviral therapy |
| GB0908952.5 | 2009-05-22 | ||
| PCT/EP2009/007958 WO2010049182A2 (en) | 2008-10-29 | 2009-10-29 | Treatment of retroviral reservoirs exploiting oxidative stress |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506884A JP2012506884A (ja) | 2012-03-22 |
| JP2012506884A5 true JP2012506884A5 (enExample) | 2012-12-13 |
| JP5779503B2 JP5779503B2 (ja) | 2015-09-16 |
Family
ID=41596151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533630A Active JP5779503B2 (ja) | 2008-10-29 | 2009-10-29 | 酸化ストレスを用いるレトロウイルスレゼルボアの処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US8785493B2 (enExample) |
| EP (1) | EP2349245B1 (enExample) |
| JP (1) | JP5779503B2 (enExample) |
| ES (1) | ES2600789T3 (enExample) |
| PL (1) | PL2349245T3 (enExample) |
| WO (1) | WO2010049182A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009289649B2 (en) | 2008-09-03 | 2016-05-05 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
| US9719069B2 (en) | 2009-01-27 | 2017-08-01 | University Of Utah Research Foundation | Methods and compositions relating to viral latency |
| GB201011921D0 (en) * | 2010-07-15 | 2010-09-01 | Sutan Anwar | Method for gas chromatography analysis and maintenance |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| JP6250403B2 (ja) | 2011-02-28 | 2017-12-20 | バイオマリン ファーマシューティカル インク | ヒストン脱アセチル化酵素阻害剤 |
| CN102727523A (zh) * | 2011-04-02 | 2012-10-17 | 复旦大学 | 一种具有抗hiv潜伏作用的药物及其用途 |
| PT2970139T (pt) | 2013-03-15 | 2018-08-01 | Biomarin Pharm Inc | Inibidores de hdac |
| WO2014201426A2 (en) * | 2013-06-14 | 2014-12-18 | University Of Utah Research Foundation | Triazol-1-ol analogs anti-retroviral latency drugs |
| US10184933B2 (en) | 2013-10-01 | 2019-01-22 | The J. David Gladstone Industries | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
| CN109414454A (zh) * | 2016-05-03 | 2019-03-01 | 加莱拉实验室有限责任公司 | 用于癌症治疗的组合疗法 |
| US11065221B2 (en) * | 2017-03-23 | 2021-07-20 | Istituto Superiore di Sanità | Buthionine sulfoximine and a metallodrug for the treatment of cancer, HIV or a rheumatic disease |
| WO2021211792A1 (en) * | 2020-04-15 | 2021-10-21 | Georgia State University Research Foundation, Inc. | Treatment of coronavirus infections with auranofin |
| CN115093359B (zh) * | 2022-06-23 | 2023-06-09 | 山东第一医科大学(山东省医学科学院) | 一种化合物、药物组合物及其在扩张血管或抗病毒领域的应用 |
| CN116947763A (zh) * | 2023-07-11 | 2023-10-27 | 郑州大学 | 2-巯基-5-氰基-6-芳基嘧啶杂环类化合物、制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232685B2 (en) * | 2001-12-19 | 2007-06-19 | The Regents Of The Universtiy Of California | Cell lines with latent immunodeficiency virus and methods of use thereof |
| AU2002351898A1 (en) * | 2001-12-21 | 2003-07-09 | Universite Libre De Bruxelles | Method for obtaining the elimination of integrated and functional viruses from infected mammal cells |
| US8247613B2 (en) * | 2006-04-17 | 2012-08-21 | The J. David Gladstone Institutes | Methods and compositions for the synergistic activation of latent HIV |
-
2009
- 2009-10-29 PL PL09759664T patent/PL2349245T3/pl unknown
- 2009-10-29 ES ES09759664.7T patent/ES2600789T3/es active Active
- 2009-10-29 JP JP2011533630A patent/JP5779503B2/ja active Active
- 2009-10-29 US US13/125,325 patent/US8785493B2/en active Active
- 2009-10-29 EP EP09759664.7A patent/EP2349245B1/en active Active
- 2009-10-29 WO PCT/EP2009/007958 patent/WO2010049182A2/en not_active Ceased
-
2014
- 2014-06-20 US US14/310,115 patent/US20150024065A1/en not_active Abandoned
-
2016
- 2016-12-21 US US15/386,336 patent/US20170157174A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008509166A5 (enExample) | ||
| RU2370495C2 (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
| EA201991515A1 (ru) | N-[4-фтор-5-[[(2s,4s)-2-метил-4-[(5-метил-1,2,4-оксадиазол-3-ил)метокси]-1-пиперидил]метил]тиазол-2-ил]ацетамид в качестве ингибитора oga | |
| SA522433000B1 (ar) | مركبات فلورو ألكيل-أوكساديازول واستخداماتها | |
| RU2007125726A (ru) | Новое производное антраниловой кислоты или его соль | |
| JP2010013443A5 (enExample) | ||
| JP2014518546A5 (enExample) | ||
| EA201001508A1 (ru) | Мостиковые гетероциклические соединения в качестве ингибиторов интегразы вич | |
| MA34013B1 (fr) | Inhibiteurs du virus de l'hépatite c | |
| AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
| RU2008146993A (ru) | N-(2-тиазолил)амидные производные в качестве ингибиторов gsk-3 | |
| EA200800178A1 (ru) | Ингибиторы вируса гепатита с (hcv) | |
| BRPI0518760A2 (pt) | sal de potÁssio do composto, e, composiÇço farmacÊutica | |
| RU2009134516A (ru) | Фармацевтическая композиция, содержащая производное пиразина, и способ применения производного пиразина в комбинации | |
| EA200400616A1 (ru) | ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β | |
| JP5779503B2 (ja) | 酸化ストレスを用いるレトロウイルスレゼルボアの処置 | |
| AR072317A1 (es) | Dihidro oxo azinil isoxazolinas herbicidas de seis miembros | |
| EA202090977A1 (ru) | Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild) | |
| RU2013140169A (ru) | Противоопухолевое терапевтическое средство | |
| JP2019510082A5 (enExample) | ||
| RU2014145819A (ru) | Бициклическое соединение | |
| BR112015028760A2 (pt) | compostos para inibição de cepas de integrase do hiv-1 resistentes a drogas | |
| ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren | |
| RU2012137245A (ru) | Индуктор считывания и терапевтический агент для генетических заболеваний, вызванных мутациями типа нонсенс-мутаций | |
| EA201101305A1 (ru) | Лечение рака поджелудочной железы |